Marktanalyse - Colon Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
722 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Colon Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer — Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 8

Colon Cancer Overview 9

Therapeutics Development 10

Colon Cancer - Therapeutics under Development by Companies 12

Colon Cancer - Therapeutics under Investigation by Universities/Institutes 23

Colon Cancer - Pipeline Products Glance 26

Colon Cancer - Products under Development by Companies 29

Colon Cancer - Products under Investigation by Universities/Institutes 42

Colon Cancer - Companies Involved in Therapeutics Development 46

Colon Cancer - Therapeutics Assessment 179

Drug Profiles 203

Colon Cancer - Dormant Projects 660

Colon Cancer - Discontinued Products 680

Colon Cancer - Product Development Milestones 681

Appendix 692





List of Tables

Number of Products under Development for Colon Cancer, H2 2016 39

Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Development by Companies, H2 2016 (Contd..1) 42

Number of Products under Development by Companies, H2 2016 (Contd..2) 43

Number of Products under Development by Companies, H2 2016 (Contd..3) 44

Number of Products under Development by Companies, H2 2016 (Contd..4) 45

Number of Products under Development by Companies, H2 2016 (Contd..5) 46

Number of Products under Development by Companies, H2 2016 (Contd..6) 47

Number of Products under Development by Companies, H2 2016 (Contd..7) 48

Number of Products under Development by Companies, H2 2016 (Contd..8) 49

Number of Products under Development by Companies, H2 2016 (Contd..9) 50

Number of Products under Development by Companies, H2 2016 (Contd..10) 51

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54

Comparative Analysis by Late Stage Development, H2 2016 55

Comparative Analysis by Clinical Stage Development, H2 2016 56

Comparative Analysis by Early Stage Development, H2 2016 57

Products under Development by Companies, H2 2016 58

Products under Development by Companies, H2 2016 (Contd..1) 59

Products under Development by Companies, H2 2016 (Contd..2) 60

Products under Development by Companies, H2 2016 (Contd..3) 61

Products under Development by Companies, H2 2016 (Contd..4) 62

Products under Development by Companies, H2 2016 (Contd..5) 63

Products under Development by Companies, H2 2016 (Contd..6) 64

Products under Development by Companies, H2 2016 (Contd..7) 65

Products under Development by Companies, H2 2016 (Contd..8) 66

Products under Development by Companies, H2 2016 (Contd..9) 67

Products under Development by Companies, H2 2016 (Contd..10) 68

Products under Development by Companies, H2 2016 (Contd..11) 69

Products under Development by Companies, H2 2016 (Contd..12) 70

Products under Investigation by Universities/Institutes, H2 2016 71

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 72

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74

Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 75

Colon Cancer - Pipeline by Adamed Sp z oo, H2 2016 76

Colon Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 77

Colon Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 78

Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 79

Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 80

Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 81

Colon Cancer - Pipeline by Affimed GmbH, H2 2016 82

Colon Cancer - Pipeline by Agenus Inc, H2 2016 83

Colon Cancer - Pipeline by AGV Discovery SAS, H2 2016 84

Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 85

Colon Cancer - Pipeline by Almac Discovery Ltd, H2 2016 86

Colon Cancer - Pipeline by Ambrx Inc, H2 2016 87

Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 88

Colon Cancer - Pipeline by AndroScience Corp, H2 2016 89

Colon Cancer - Pipeline by Aphios Corp, H2 2016 90

Colon Cancer - Pipeline by Aposense Ltd, H2 2016 91

Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2016 92

Colon Cancer - Pipeline by AstraZeneca Plc, H2 2016 93

Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 94

Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2016 95

Colon Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 96

Colon Cancer - Pipeline by BioCancell Ltd, H2 2016 97

Colon Cancer - Pipeline by Biogazelle NV, H2 2016 98

Colon Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 99

Colon Cancer - Pipeline by Blirt SA, H2 2016 100

Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 101

Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 102

Colon Cancer - Pipeline by Celprogen Inc, H2 2016 103

Colon Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 104

Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 105

Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 106

Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2016 107

Colon Cancer - Pipeline by CZ BioMed Corp, H2 2016 108

Colon Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109

Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2016 110

Colon Cancer - Pipeline by Eli Lilly and Company, H2 2016 111

Colon Cancer - Pipeline by EntreChem SL, H2 2016 112

Colon Cancer - Pipeline by EnzymeBioSystems, H2 2016 113

Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 114

Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 115

Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2016 116

Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2016 117

Colon Cancer - Pipeline by Grunenthal GmbH, H2 2016 118

Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016 119

Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2016 120

Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 121

Colon Cancer - Pipeline by Helix BioPharma Corp, H2 2016 122

Colon Cancer - Pipeline by Histogen Inc, H2 2016 123

Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2016 124

Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2016 125

Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016 126

Colon Cancer - Pipeline by Immunome Inc, H2 2016 127

Colon Cancer - Pipeline by Immunomedics Inc, H2 2016 128

Colon Cancer - Pipeline by Immunotope Inc, H2 2016 129

Colon Cancer - Pipeline by Immupharma Plc, H2 2016 130

Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016 131

Colon Cancer - Pipeline by Incuron LLC, H2 2016 132

Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2016 133

Colon Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016 134

Colon Cancer - Pipeline by Innopharmax Inc, H2 2016 135

Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 136

Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 137

Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 138

Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 139

Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016 140

Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 141

Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 142

Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 143

Colon Cancer - Pipeline by Lipocure Ltd, H2 2016 144

Colon Cancer - Pipeline by Lupin Ltd, H2 2016 145

Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2016 146

Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 147

Colon Cancer - Pipeline by MacroGenics Inc, H2 2016 148

Colon Cancer - Pipeline by MaxiVAX SA, H2 2016 149

Colon Cancer - Pipeline by Meabco A/S, H2 2016 150

Colon Cancer - Pipeline by Medicenna Therapeutics Inc, H2 2016 151

Colon Cancer - Pipeline by Microlin Bio, Inc., H2 2016 152

Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2016 153

Colon Cancer - Pipeline by MolMed SpA, H2 2016 154

Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2016 155

Colon Cancer - Pipeline by Multimmune GmbH, H2 2016 156

Colon Cancer - Pipeline by NormOxys Inc, H2 2016 157

Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 158

Colon Cancer - Pipeline by Novartis AG, H2 2016 159

Colon Cancer - Pipeline by Omeros Corp, H2 2016 160

Colon Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 161

Colon Cancer - Pipeline by Oncovir Inc, H2 2016 162

Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 163

Colon Cancer - Pipeline by Orega Biotech SAS, H2 2016 164

Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2016 165

Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 166

Colon Cancer - Pipeline by Patrys Ltd, H2 2016 167

Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2016 168

Colon Cancer - Pipeline by Pharminox Ltd, H2 2016 169

Colon Cancer - Pipeline by Philogen SpA, H2 2016 170

Colon Cancer - Pipeline by Pique Therapeutics, H2 2016 171

Colon Cancer - Pipeline by Plexxikon Inc, H2 2016 172

Colon Cancer - Pipeline by ProNAi Therapeutics Inc, H2 2016 173

Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2016 174

Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 175

Colon Cancer - Pipeline by Qu Biologics Inc, H2 2016 176

Colon Cancer - Pipeline by Recce Pty Ltd, H2 2016 177

Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 178

Colon Cancer - Pipeline by Rgenix Inc, H2 2016 179

Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2016 180

Colon Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 181

Colon Cancer - Pipeline by Sellas Inc, H2 2016 182

Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2016 183

Colon Cancer - Pipeline by Sirnaomics Inc, H2 2016 184

Colon Cancer - Pipeline by SOM Biotech SL, H2 2016 185

Colon Cancer - Pipeline by Somantix BV, H2 2016 186

Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 187

Colon Cancer - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 188

Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016 189

Colon Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 190

Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2016 191

Colon Cancer - Pipeline by TaiRx Inc, H2 2016 192

Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 193

Colon Cancer - Pipeline by Takis Srl, H2 2016 194

Colon Cancer - Pipeline by Targovax ASA, H2 2016 195

Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 196

Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2016 197

Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2016 198

Colon Cancer - Pipeline by TyrNovo Ltd, H2 2016 199

Colon Cancer - Pipeline by Vaccinogen Inc, H2 2016 200

Colon Cancer - Pipeline by Vault Pharma Inc, H2 2016 201

Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2016 202

Colon Cancer - Pipeline by Vaximm AG, H2 2016 203

Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2016 204

Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2016 205

Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 206

Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016 207

Assessment by Monotherapy Products, H2 2016 208

Assessment by Combination Products, H2 2016 209

Number of Products by Stage and Target, H2 2016 211

Number of Products by Stage and Mechanism of Action, H2 2016 220

Number of Products by Stage and Route of Administration, H2 2016 229

Number of Products by Stage and Molecule Type, H2 2016 231

Colon Cancer - Dormant Projects, H2 2016 689

Colon Cancer - Dormant Projects (Contd..1), H2 2016 690

Colon Cancer - Dormant Projects (Contd..2), H2 2016 691

Colon Cancer - Dormant Projects (Contd..3), H2 2016 692

Colon Cancer - Dormant Projects (Contd..4), H2 2016 693

Colon Cancer - Dormant Projects (Contd..5), H2 2016 694

Colon Cancer - Dormant Projects (Contd..6), H2 2016 695

Colon Cancer - Dormant Projects (Contd..7), H2 2016 696

Colon Cancer - Dormant Projects (Contd..8), H2 2016 697

Colon Cancer - Dormant Projects (Contd..9), H2 2016 698

Colon Cancer - Dormant Projects (Contd..10), H2 2016 699

Colon Cancer - Dormant Projects (Contd..11), H2 2016 700

Colon Cancer - Dormant Projects (Contd..12), H2 2016 701

Colon Cancer - Dormant Projects (Contd..13), H2 2016 702

Colon Cancer - Dormant Projects (Contd..14), H2 2016 703

Colon Cancer - Dormant Projects (Contd..15), H2 2016 704

Colon Cancer - Dormant Projects (Contd..16), H2 2016 705

Colon Cancer - Dormant Projects (Contd..17), H2 2016 706

Colon Cancer - Dormant Projects (Contd..18), H2 2016 707

Colon Cancer - Dormant Projects (Contd..19), H2 2016 708

Colon Cancer - Discontinued Products, H2 2016 709





List of Figures

Number of Products under Development for Colon Cancer, H2 2016 39

Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Comparative Analysis by Clinical Stage Development, H2 2016 56

Comparative Analysis by Early Stage Products, H2 2016 57

Assessment by Monotherapy Products, H2 2016 208

Assessment by Combination Products, H2 2016 209

Number of Products by Top 10 Targets, H2 2016 210

Number of Products by Stage and Top 10 Targets, H2 2016 210

Number of Products by Top 10 Mechanism of Actions, H2 2016 219

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 219

Number of Products by Top 10 Routes of Administration, H2 2016 228

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228

Number of Products by Top 10 Molecule Types, H2 2016 230

Number of Products by Stage and Top 10 Molecule Types, H2 2016 230

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus